1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 CIS PROLINE - PRO 75 Clore, G.M. Qin, J. Gronenborn, A.M. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking H2 O 18.015 WATER non-polymer C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking UK Structure STRUE6 2005 0969-2126 3 289 297 10.1016/S0969-2126(01)00159-9 7788295 Solution structure of human thioredoxin in a mixed disulfide intermediate complex with its target peptide from the transcription factor NF kappa B. 1995 10.2210/pdb1mdj/pdb pdb_00001mdj 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 11592.125 THIOREDOXIN 1 man polymer 1557.755 TARGET SITE IN HUMAN NFKB 1 man polymer 18.015 water 6 nat water no no MVKQIESKTAFQEALDAAGDKLVVVDFSATWCGPAKMIKPFFHSLSEKYSNVIFLEVDVDDAQDVASEAEVKATPTFQFF KKGQKVGEFSGANKEKLEATINELV MVKQIESKTAFQEALDAAGDKLVVVDFSATWCGPAKMIKPFFHSLSEKYSNVIFLEVDVDDAQDVASEAEVKATPTFQFF KKGQKVGEFSGANKEKLEATINELV A polypeptide(L) no no FRFRYVCEGPSHG FRFRYVCEGPSHG B polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n human Homo sample 9606 Homo sapiens database_2 pdbx_database_status pdbx_struct_assembly pdbx_struct_oper_list struct_ref_seq_dif repository Initial release Version format compliance Version format compliance Database references Derived calculations Other 1 0 1995-06-03 1 1 2008-03-24 1 2 2011-07-13 1 3 2022-02-23 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_database_status.process_site _struct_ref_seq_dif.details Y BNL 1995-02-27 REL HOH water AT POSITION 74 THR WAS FOUND BY WOLMAN ET AL., JOURNAL OF BIOCHEMISTRY 263, 15506 (1988). 30 THE 3D STRUCTURE OF THE HUMAN THIOREDOXIN-NFKB PEPTIDE COMPLEX IN SOLUTION BY NMR IS BASED ON 3213 EXPERIMENTAL RESTRAINTS COMPRISING: 2546 STRUCTURE USEFUL INTERPROTON DISTANCE RESTRAINTS 36 RESTRAINTS FOR 18 BACKBONE H-BONDS 44 RESTRAINTS FOR 6 BOUND WATER MOLECULES 300 TORSION ANGLE RESTRAINTS (104 PHI, 76 PSI, 78 CHI1 AND 31 CHI2 FOR HUMAN THIOREDOXIN, AND 7 CHI1 AND 4 CHI2 RESTRAINTS FOR THE NFKB PEPTIDE) 88 HN-HALPHA THREE-BOND COUPLING CONSTANTS 102 13CALPHA AND 97 13CB CHEMICAL SHIFT RESTRAINTS. THE BREAKDOWN OF THE INTERPROTON DISTANCE RESTRAINTS IS AS FOLLOWS: INTRAMOLECULAR HTRX RESTRAINTS: 503 SEQUENTIAL 437 SHORT RANGE (1 < |I-J|<=5) 727 LONG RANGE (|I-J|>5) 690 INTRARESIDUE INTRAMOLECULAR PEPTIDE RESTRAINTS: 115 INTERMOLECULAR HTRX-NFKB: 74 THE STRUCTURES ARE CALCULATED USING THE HYBRID METRIC MATRIX DISTANCE GEOMETRY-DYNAMICAL SIMULATED ANNEALING METHOD DESCRIBED BY: NILGES, M., CLORE, G.M. & GRONENBORN, A.M. (1988) FEBS LETT 229, 317 - 324. ALL STRUCTURAL STATISTICS ARE GIVEN IN THE REFERENCE. THE STRUCTURE FOUND IN PDB ENTRY 1MDI IS THE RESTRAINED MINIMIZED AVERAGE STRUCTURE: (SA)R. THIS IS OBTAINED BY FIRST AVERAGING THE COORDINATES OF THE INDIVIDUAL 60 DYNAMICAL SIMULATED ANNEALING SA STRUCTURES BEST FITTED TO RESIDUES 1 - 105 OF HTRX AND RESIDUES 57 - 67 OF THE PEPTIDE AND SUBJECTING THE RESULTING COORDINATES TO RESTRAINED MINIMIZATION. THE LAST NUMBER COLUMN IN THIS SET OF COORDINATES (THE B-FACTOR COLUMN IN X-RAY STRUCTURES) GIVES THE AVERAGE RMS DIFFERENCE BETWEEN THE INDIVIDUAL SA STRUCTURES AND THE MEAN STRUCTURE. THE NUMBERS IN THE LAST COLUMN OF THE INDIVIDUAL STRUCTURES HAVE NO MEANING. HOH 1 3 HOH HOH 106 A HOH 2 3 HOH HOH 107 A HOH 3 3 HOH HOH 108 A HOH 4 3 HOH HOH 109 A HOH 5 3 HOH HOH 110 A HOH 6 3 HOH HOH 111 A MET 1 n 1 MET 1 A VAL 2 n 2 VAL 2 A LYS 3 n 3 LYS 3 A GLN 4 n 4 GLN 4 A ILE 5 n 5 ILE 5 A GLU 6 n 6 GLU 6 A SER 7 n 7 SER 7 A LYS 8 n 8 LYS 8 A THR 9 n 9 THR 9 A ALA 10 n 10 ALA 10 A PHE 11 n 11 PHE 11 A GLN 12 n 12 GLN 12 A GLU 13 n 13 GLU 13 A ALA 14 n 14 ALA 14 A LEU 15 n 15 LEU 15 A ASP 16 n 16 ASP 16 A ALA 17 n 17 ALA 17 A ALA 18 n 18 ALA 18 A GLY 19 n 19 GLY 19 A ASP 20 n 20 ASP 20 A LYS 21 n 21 LYS 21 A LEU 22 n 22 LEU 22 A VAL 23 n 23 VAL 23 A VAL 24 n 24 VAL 24 A VAL 25 n 25 VAL 25 A ASP 26 n 26 ASP 26 A PHE 27 n 27 PHE 27 A SER 28 n 28 SER 28 A ALA 29 n 29 ALA 29 A THR 30 n 30 THR 30 A TRP 31 n 31 TRP 31 A CYS 32 n 32 CYS 32 A GLY 33 n 33 GLY 33 A PRO 34 n 34 PRO 34 A ALA 35 n 35 ALA 35 A LYS 36 n 36 LYS 36 A MET 37 n 37 MET 37 A ILE 38 n 38 ILE 38 A LYS 39 n 39 LYS 39 A PRO 40 n 40 PRO 40 A PHE 41 n 41 PHE 41 A PHE 42 n 42 PHE 42 A HIS 43 n 43 HIS 43 A SER 44 n 44 SER 44 A LEU 45 n 45 LEU 45 A SER 46 n 46 SER 46 A GLU 47 n 47 GLU 47 A LYS 48 n 48 LYS 48 A TYR 49 n 49 TYR 49 A SER 50 n 50 SER 50 A ASN 51 n 51 ASN 51 A VAL 52 n 52 VAL 52 A ILE 53 n 53 ILE 53 A PHE 54 n 54 PHE 54 A LEU 55 n 55 LEU 55 A GLU 56 n 56 GLU 56 A VAL 57 n 57 VAL 57 A ASP 58 n 58 ASP 58 A VAL 59 n 59 VAL 59 A ASP 60 n 60 ASP 60 A ASP 61 n 61 ASP 61 A ALA 62 n 62 ALA 62 A GLN 63 n 63 GLN 63 A ASP 64 n 64 ASP 64 A VAL 65 n 65 VAL 65 A ALA 66 n 66 ALA 66 A SER 67 n 67 SER 67 A GLU 68 n 68 GLU 68 A ALA 69 n 69 ALA 69 A GLU 70 n 70 GLU 70 A VAL 71 n 71 VAL 71 A LYS 72 n 72 LYS 72 A ALA 73 n 73 ALA 73 A THR 74 n 74 THR 74 A PRO 75 n 75 PRO 75 A THR 76 n 76 THR 76 A PHE 77 n 77 PHE 77 A GLN 78 n 78 GLN 78 A PHE 79 n 79 PHE 79 A PHE 80 n 80 PHE 80 A LYS 81 n 81 LYS 81 A LYS 82 n 82 LYS 82 A GLY 83 n 83 GLY 83 A GLN 84 n 84 GLN 84 A LYS 85 n 85 LYS 85 A VAL 86 n 86 VAL 86 A GLY 87 n 87 GLY 87 A GLU 88 n 88 GLU 88 A PHE 89 n 89 PHE 89 A SER 90 n 90 SER 90 A GLY 91 n 91 GLY 91 A ALA 92 n 92 ALA 92 A ASN 93 n 93 ASN 93 A LYS 94 n 94 LYS 94 A GLU 95 n 95 GLU 95 A LYS 96 n 96 LYS 96 A LEU 97 n 97 LEU 97 A GLU 98 n 98 GLU 98 A ALA 99 n 99 ALA 99 A THR 100 n 100 THR 100 A ILE 101 n 101 ILE 101 A ASN 102 n 102 ASN 102 A GLU 103 n 103 GLU 103 A LEU 104 n 104 LEU 104 A VAL 105 n 105 VAL 105 A PHE 1 n 1 PHE 1 B ARG 2 n 2 ARG 2 B PHE 3 n 3 PHE 3 B ARG 4 n 4 ARG 4 B TYR 5 n 5 TYR 5 B VAL 6 n 6 VAL 6 B CYS 7 n 7 CYS 7 B GLU 8 n 8 GLU 8 B GLY 9 n 9 GLY 9 B PRO 10 n 10 PRO 10 B SER 11 n 11 SER 11 B HIS 12 n 12 HIS 12 B GLY 13 n 13 GLY 13 B author_defined_assembly 2 dimeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 A O LYS 3 A O LYS 3 A N PHE 54 A N PHE 54 A O ILE 53 A O ILE 53 A N VAL 24 A N VAL 24 A O VAL 23 A O VAL 23 A N PHE 80 A N PHE 80 A O PHE 77 A O PHE 77 A N PHE 89 A N PHE 89 2 A A H H2 ASP HOH 60 108 1.32 5 A A H H2 ASP HOH 60 108 1.14 10 A A H H2 LEU HOH 22 111 1.34 11 A A H H2 LEU HOH 22 111 1.26 12 A A H H1 ASP HOH 60 108 1.32 13 A A H H2 LEU HOH 22 111 1.30 15 A A H H2 LYS HOH 82 106 1.31 23 A A H H1 ASP HOH 60 108 1.29 23 A A H H2 LEU HOH 22 111 1.32 26 A A H H2 ASP HOH 60 108 1.30 1 A SER 28 -110.51 -162.67 1 A PHE 41 -110.10 -76.94 1 A SER 90 -102.77 -169.70 1 A ALA 92 -57.01 94.35 1 B ARG 4 -142.08 -105.00 1 B TYR 5 -109.74 -169.81 1 B GLU 8 -83.17 44.63 1 B PRO 10 -67.33 25.76 1 B HIS 12 -58.63 -94.79 2 A PRO 40 -59.68 -8.16 2 A PHE 41 -108.19 -70.30 2 A SER 90 -103.97 -163.83 2 A ALA 92 -53.18 94.36 2 B ARG 4 -138.70 -86.48 2 B GLU 8 -83.92 45.00 2 B PRO 10 -66.47 22.99 3 A SER 28 -107.33 -162.46 3 A PHE 41 -108.77 -78.23 3 A LEU 45 -49.74 -13.27 3 A LYS 82 56.55 17.19 3 A SER 90 -103.36 -167.95 3 A ALA 92 -56.28 96.44 3 B ARG 2 -164.27 62.64 3 B ARG 4 -145.69 -110.43 3 B GLU 8 -83.25 47.57 3 B PRO 10 -68.38 26.94 4 A PHE 41 -111.20 -80.61 4 A VAL 59 -52.06 -0.58 4 A GLU 88 -173.71 147.45 4 A SER 90 -102.76 -167.88 4 A ALA 92 -60.81 95.11 4 B ARG 2 -167.74 21.92 4 B ARG 4 -150.68 -105.27 4 B GLU 8 -83.00 44.18 4 B PRO 10 -66.34 23.13 4 B HIS 12 -156.17 -122.04 5 A PHE 41 -103.54 -70.21 5 A VAL 59 -56.87 -2.06 5 A ALA 92 -56.55 94.69 5 B ARG 4 -149.17 -93.20 5 B TYR 5 -116.03 -166.29 5 B GLU 8 -84.54 42.91 5 B PRO 10 -66.39 24.36 6 A PHE 41 -110.39 -72.19 6 A VAL 59 -54.14 -6.86 6 A SER 90 -103.07 -163.70 6 A ALA 92 -53.09 94.53 6 B ARG 4 -150.23 -99.88 6 B GLU 8 -82.97 46.01 6 B PRO 10 -68.24 25.52 7 A PHE 41 -113.57 -70.36 7 A LYS 82 58.19 19.79 7 A SER 90 -103.04 -161.45 7 A ALA 92 -53.64 98.94 7 B ARG 4 -148.15 -104.27 7 B TYR 5 -112.23 -167.53 7 B GLU 8 -82.63 42.95 7 B PRO 10 -70.76 24.70 7 B HIS 12 -55.58 -80.89 8 A SER 28 -105.05 -164.52 8 A PHE 41 -103.16 -71.57 8 A SER 90 -103.15 -167.29 8 A ALA 92 -55.10 93.61 8 B ARG 2 -147.07 55.01 8 B ARG 4 -150.54 -110.25 8 B GLU 8 -82.84 46.71 8 B PRO 10 -67.45 24.99 9 A PHE 41 -103.00 -70.51 9 A VAL 59 -55.77 -9.90 9 A ALA 92 -50.50 97.07 9 B ARG 4 -150.49 -102.07 9 B GLU 8 -83.57 42.82 9 B PRO 10 -66.53 24.55 9 B HIS 12 -65.40 -148.71 10 A PHE 41 -111.04 -77.60 10 A VAL 59 -54.39 -2.69 10 A SER 90 -102.42 -163.04 10 A ALA 92 -52.58 96.78 10 B ARG 2 -159.13 61.96 10 B ARG 4 -150.29 -102.92 10 B GLU 8 -83.63 45.79 10 B PRO 10 -66.30 22.68 11 A PHE 41 -103.48 -71.78 11 A VAL 59 -58.93 -2.85 11 A SER 90 -103.40 -168.72 11 A ALA 92 -51.49 97.56 11 B ARG 4 -141.97 -84.40 11 B TYR 5 -125.31 -169.39 11 B GLU 8 -83.37 44.51 11 B PRO 10 -67.98 25.73 11 B HIS 12 -160.72 -61.27 12 A SER 28 -108.72 -164.75 12 A PHE 41 -103.62 -69.83 12 A SER 90 -101.69 -161.78 12 A ALA 92 -56.15 99.15 12 B ARG 2 -152.01 62.03 12 B ARG 4 -144.53 -102.90 12 B GLU 8 -83.20 44.42 12 B PRO 10 -67.58 24.87 12 B HIS 12 51.54 -92.30 13 A PHE 41 -111.19 -72.60 13 A VAL 59 -59.07 -2.94 13 A SER 90 -102.51 -160.77 13 A ALA 92 -56.65 89.99 13 B ARG 2 -171.53 78.27 13 B ARG 4 -150.45 -108.53 13 B GLU 8 -83.74 44.98 13 B PRO 10 -67.45 20.78 14 A SER 28 -107.53 -163.73 14 A PHE 41 -99.67 -69.80 14 A SER 90 -103.64 -162.49 14 A ALA 92 -63.57 95.39 14 B ARG 4 -144.54 -107.87 14 B GLU 8 -83.70 42.01 14 B PRO 10 -66.89 21.45 14 B HIS 12 -165.79 -144.04 15 A PHE 41 -102.37 -77.67 15 A SER 90 -103.50 -168.52 15 A ALA 92 -56.58 95.77 15 B ARG 4 -145.59 -86.86 15 B TYR 5 -123.82 -167.01 15 B GLU 8 -83.14 46.13 15 B PRO 10 -65.97 18.65 16 A PHE 41 -104.51 -72.67 16 A SER 90 -104.31 -167.07 16 A ALA 92 -58.85 96.96 16 B ARG 4 -143.06 -99.45 16 B GLU 8 -83.87 46.77 16 B PRO 10 -70.11 26.84 17 A SER 28 -103.74 -163.89 17 A PHE 41 -109.69 -77.10 17 A LEU 45 -49.63 -14.99 17 A SER 90 -103.61 -165.64 17 A ALA 92 -53.53 95.68 17 B ARG 4 -150.24 -81.82 17 B GLU 8 -82.43 44.72 17 B PRO 10 -69.65 22.84 18 A PHE 41 -108.64 -77.23 18 A VAL 59 -52.05 -9.81 18 A SER 90 -104.36 -166.99 18 A ALA 92 -58.15 95.00 18 B ARG 4 -132.67 -106.88 18 B GLU 8 -83.31 45.33 18 B PRO 10 -65.87 20.29 18 B HIS 12 -161.54 -70.92 19 A SER 28 -104.88 -164.89 19 A PHE 41 -110.29 -73.67 19 A LEU 45 -49.05 -13.10 19 A SER 90 -103.20 -161.34 19 A ALA 92 -53.58 98.64 19 B ARG 2 -169.20 94.48 19 B ARG 4 -150.71 -110.91 19 B GLU 8 -83.85 48.71 19 B PRO 10 -66.48 21.59 20 A PRO 40 -67.39 0.65 20 A PHE 41 -119.00 -78.42 20 A LEU 45 -49.25 -16.72 20 A VAL 59 -56.94 -0.90 20 A ALA 62 -108.01 43.26 20 A LYS 82 57.05 9.42 20 A SER 90 -102.07 -163.76 20 A ALA 92 -54.62 97.53 20 B ARG 4 -150.45 -88.16 20 B GLU 8 -83.30 49.45 20 B PRO 10 -66.61 25.57 20 B HIS 12 51.56 -127.67 21 A PHE 41 -107.63 -76.51 21 A ALA 92 -59.87 92.12 21 B ARG 2 -154.10 69.06 21 B ARG 4 -143.57 -101.05 21 B TYR 5 -114.72 -165.43 21 B GLU 8 -83.80 41.99 21 B PRO 10 -66.85 25.71 22 A SER 28 -111.94 -162.21 22 A PHE 41 -105.97 -73.27 22 A VAL 59 -59.48 -8.57 22 A SER 90 -102.29 -164.82 22 A ALA 92 -54.51 98.85 22 B ARG 4 -147.41 -101.05 22 B TYR 5 -117.32 -169.37 22 B GLU 8 -83.00 46.51 22 B PRO 10 -68.37 26.32 23 A SER 28 -103.37 -162.88 23 A PHE 41 -110.66 -78.02 23 A LEU 45 -49.39 -16.28 23 A ALA 92 -53.83 96.72 23 B ARG 4 -138.07 -108.48 23 B GLU 8 -82.89 45.49 23 B PRO 10 -67.31 24.53 24 A PHE 41 -104.66 -70.12 24 A SER 90 -107.49 -168.44 24 A ALA 92 -49.34 92.14 24 B ARG 4 -144.29 -105.29 24 B TYR 5 -109.67 -167.21 24 B GLU 8 -83.43 44.76 24 B PRO 10 -67.20 24.66 24 B HIS 12 -168.11 96.64 25 A PHE 41 -111.88 -74.36 25 A LEU 45 -49.14 -15.97 25 A SER 90 -102.58 -167.47 25 A ALA 92 -58.69 94.05 25 B ARG 2 -145.58 56.19 25 B ARG 4 -133.43 -91.17 25 B GLU 8 -83.93 42.44 25 B PRO 10 -66.27 20.77 25 B HIS 12 -46.79 155.50 26 A PHE 41 -107.69 -75.69 26 A SER 90 -103.03 -169.75 26 A ALA 92 -57.08 95.97 26 B ARG 2 -150.87 72.17 26 B ARG 4 -147.86 -81.28 26 B GLU 8 -83.20 44.99 26 B PRO 10 -67.16 22.73 27 A PRO 40 -65.55 7.04 27 A PHE 41 -127.80 -74.51 27 A LEU 45 -49.49 -16.77 27 A SER 90 -101.04 -162.47 27 A ALA 92 -56.20 96.66 27 B ARG 4 -146.86 -92.66 27 B TYR 5 -127.22 -169.22 27 B GLU 8 -82.97 45.89 27 B PRO 10 -68.41 27.14 28 A SER 28 -103.05 -164.21 28 A PHE 41 -111.43 -79.51 28 A SER 90 -102.59 -161.51 28 A ALA 92 -59.71 97.33 28 B ARG 4 -136.17 -79.85 28 B TYR 5 -129.02 -167.48 28 B GLU 8 -83.18 47.18 28 B PRO 10 -69.01 20.93 29 A PHE 41 -111.46 -78.00 29 A LEU 45 -49.05 -14.10 29 A VAL 59 -53.43 -8.90 29 A SER 90 -102.83 -169.56 29 A ALA 92 -58.78 96.96 29 B ARG 2 -157.39 60.21 29 B ARG 4 -150.99 -112.27 29 B GLU 8 -82.82 41.80 29 B PRO 10 -68.07 27.92 30 A SER 28 -105.55 -164.70 30 A PHE 41 -104.37 -73.93 30 A SER 90 -103.38 -162.97 30 A ALA 92 -58.72 93.29 30 B ARG 4 -140.72 -102.19 30 B TYR 5 -109.27 -169.85 30 B GLU 8 -83.14 46.13 30 B PRO 10 -67.84 25.35 HIGH RESOLUTION SOLUTION NMR STRUCTURE OF MIXED DISULFIDE INTERMEDIATE BETWEEN HUMAN THIOREDOXIN (C35A, C62A, C69A, C73A) MUTANT AND A 13 RESIDUE PEPTIDE COMPRISING ITS TARGET SITE IN HUMAN NFKB (RESIDUES 56-68 OF THE P50 SUBUNIT OF NFKB) 1 N N 2 N N 3 N N A LYS 8 A LYS 8 HELX_P A ALA 17 A ALA 17 1 1 10 A GLY 33 A GLY 33 HELX_P A PHE 42 A PHE 42 1 2 10 A SER 44 A SER 44 HELX_P A LYS 48 A LYS 48 5 3 5 A GLN 63 A GLN 63 HELX_P A ALA 69 A ALA 69 1 4 7 A LYS 94 A LYS 94 HELX_P A LEU 104 A LEU 104 1 5 11 disulf 2.020 A CYS 32 A SG CYS 32 1_555 B CYS 7 B SG CYS 7 1_555 COMPLEX (ELECTRON TRANSPORT/PEPTIDE) COMPLEX (ELECTRON TRANSPORT-PEPTIDE), COMPLEX (ELECTRON TRANSPORT-PEPTIDE) complex A THR 74 A THR 74 1 A PRO 75 A PRO 75 -1.41 A THR 74 A THR 74 2 A PRO 75 A PRO 75 -2.15 A THR 74 A THR 74 3 A PRO 75 A PRO 75 -1.27 A THR 74 A THR 74 4 A PRO 75 A PRO 75 -1.92 A THR 74 A THR 74 5 A PRO 75 A PRO 75 -2.38 A THR 74 A THR 74 6 A PRO 75 A PRO 75 -1.59 A THR 74 A THR 74 7 A PRO 75 A PRO 75 -1.58 A THR 74 A THR 74 8 A PRO 75 A PRO 75 -1.97 A THR 74 A THR 74 9 A PRO 75 A PRO 75 -2.03 A THR 74 A THR 74 10 A PRO 75 A PRO 75 -1.76 A THR 74 A THR 74 11 A PRO 75 A PRO 75 -1.54 A THR 74 A THR 74 12 A PRO 75 A PRO 75 -1.71 A THR 74 A THR 74 13 A PRO 75 A PRO 75 -1.88 A THR 74 A THR 74 14 A PRO 75 A PRO 75 -1.80 A THR 74 A THR 74 15 A PRO 75 A PRO 75 -1.84 A THR 74 A THR 74 16 A PRO 75 A PRO 75 -1.94 A THR 74 A THR 74 17 A PRO 75 A PRO 75 -1.77 A THR 74 A THR 74 18 A PRO 75 A PRO 75 -1.42 A THR 74 A THR 74 19 A PRO 75 A PRO 75 -1.72 A THR 74 A THR 74 20 A PRO 75 A PRO 75 -1.30 A THR 74 A THR 74 21 A PRO 75 A PRO 75 -2.19 A THR 74 A THR 74 22 A PRO 75 A PRO 75 -1.69 A THR 74 A THR 74 23 A PRO 75 A PRO 75 -1.80 A THR 74 A THR 74 24 A PRO 75 A PRO 75 -1.81 A THR 74 A THR 74 25 A PRO 75 A PRO 75 -1.96 A THR 74 A THR 74 26 A PRO 75 A PRO 75 -2.03 A THR 74 A THR 74 27 A PRO 75 A PRO 75 -1.63 A THR 74 A THR 74 28 A PRO 75 A PRO 75 -2.20 A THR 74 A THR 74 29 A PRO 75 A PRO 75 -1.78 A THR 74 A THR 74 30 A PRO 75 A PRO 75 -1.78 THIO_HUMAN UNP 1 1 P10599 VKQIESKTAFQEALDAAGDKLVVVDFSATWCGPCKMIKPFFHSLSEKYSNVIFLEVDVDDCQDVASECEVKCMPTFQFFK KGQKVGEFSGANKEKLEATINELV NFKB1_HUMAN UNP 2 1 P19838 MADDDPYGTGQMFHLNTALTHSIFNAELYSPEIPLSTDGPYLQILEQPKQRGFRFRYVCEGPSHGGLPGASSEKNKKSYP QVKICNYVGPAKVIVQLVTNGKNIHLHAHSLVGKHCEDGVCTVTAGPKDMVVGFANLGILHVTKKKVFETLEARMTEACI RGYNPGLLVHSDLAYLQAEGGGDRQLTDREKEIIRQAAVQQTKEMDLSVVRLMFTAFLPDSTGSFTRRLEPVVSDAIYDS KAPNASNLKIVRMDRTAGCVTGGEEIYLLCDKVQKDDIQIRFYEEEENGGVWEGFGDFSPTDVHRQFAIVFKTPKYKDVN ITKPASVFVQLRRKSDLETSEPKPFLYYPEIKDKEEVQRKRQKLMPNFSDSFGGGSGAGAGGGGMFGSGGGGGSTGSPGP GYGYSNYGFPPYGGITFHPGVTKSNAGVTHGTINTKFKNGPKDCAKSDDEESLTLPEKETEGEGPSLPMACTKTEPIALA STMEDKEQDMGFQDNLFLEKALQLARRHANALFDYAVTGDVKMLLAVQRHLTAVQDENGDSVLHLAIIHLHAQLVRDLLE VTSGLISDDIINMRNDLYQTPLHLAVITKQEDVVEDLLRVGADLSLLDRWGNSVLHLAAKEGHDRILSILLKSRKAAPLI DHPNGEGLNAIHIAVMSNSLPCLLLLVAAGAEVNAQEQKSGRTPLHLAVEYDNISLAGCLLLEGDAHVDSTTYDGTTPLH IAAGRGSTRLAALLKAAGADPLVENFEPLYDLDDSWEKAGEDEGVVPGTTPLDMAANWQVFDILNGKPYEPVFTSDDILP QGDMKQLTEDTRLQLCKLLEIPDPDKNWATLAQKLGLGILNNAFRLSPAPSKTLMDNYEVSGGTIKELMEALQQMGYTEA IEVIQAAFRTPATTASSPVTTAQVHCLPLSSSSTRQHIDELRDSDSVCDSGVETSFRKLSFTESLTGDSPLLSLNKMPHG YGQEGPIEGKI 1 104 1MDJ 2 105 P10599 A 1 2 105 53 65 1MDJ 1 13 P19838 B 2 1 13 1 CYS conflict ALA 35 1MDJ A P10599 UNP 34 35 1 CYS conflict ALA 62 1MDJ A P10599 UNP 61 62 1 CYS conflict ALA 69 1MDJ A P10599 UNP 68 69 1 CYS conflict ALA 73 1MDJ A P10599 UNP 72 73 1 MET conflict THR 74 1MDJ A P10599 UNP 73 74 5 parallel parallel anti-parallel anti-parallel A VAL 2 A VAL 2 A ILE 5 A ILE 5 A ILE 53 A ILE 53 A VAL 57 A VAL 57 A VAL 23 A VAL 23 A PHE 27 A PHE 27 A THR 76 A THR 76 A LYS 81 A LYS 81 A GLN 84 A GLN 84 A SER 90 A SER 90 1 P 1